Graft-vs-Host disease treatment gets boost

The European Medicines Agency (EMA) has granted Israeli biotech Enlivex “orphan” status for its ApoCell treatment to prevent Graft-vs-Host Disease.  It will speed up development of the Israeli innovation that stops rejection of transplanted cells and bone marrow.

http://www.nasdaq.com/press-release/enlivex-granted-eu-orphan-drug-designation-for-lead-product-apocell-for-graftversushost-disease-20150126-00574

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *